119 related articles for article (PubMed ID: 2868745)
1. Pharmacokinetics of flestolol in man: preliminary data.
Achari R; Hulse JD; Drissel D; Matier WL
Br J Clin Pharmacol; 1985 Dec; 20(6):691-4. PubMed ID: 2868745
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.
Achari R; Drissel D; Hulse JD; Bell V; Turlapaty P; Laddu A; Matier WL
J Clin Pharmacol; 1987 Jan; 27(1):60-4. PubMed ID: 2890664
[TBL] [Abstract][Full Text] [Related]
3. Flestolol: an ultra-short-acting beta-adrenergic blocking agent.
Barton SD; Burge J; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A36-A39. PubMed ID: 2870085
[TBL] [Abstract][Full Text] [Related]
4. Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker.
Turlapaty P; Burge J; Hulse J; Achari R; Bell V; Mosberg H; Laddu A
Clin Pharmacol Ther; 1986 May; 39(5):543-9. PubMed ID: 3698462
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of the ultra short acting beta-adrenergic antagonist flestolol in blood by liquid chromatography.
Moore P; Mai K; Lai CM
J Pharm Sci; 1986 Apr; 75(4):424-6. PubMed ID: 2873234
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker.
Strom J; Josephson M; Frishman WH; Singh B; Heilbrunn S; Osterle S; Turlapaty P; Viray R; Coe J; Bell V
J Clin Pharmacol; 1988 Mar; 28(3):276-82. PubMed ID: 2896204
[TBL] [Abstract][Full Text] [Related]
7. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic activity of flestolol, a novel ultra-short-acting beta-adrenoceptor antagonist, in the dog.
Reynolds RD; Brown BS
Eur J Pharmacol; 1986 Nov; 131(1):55-66. PubMed ID: 2880726
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.
Gillies HC; Rogers HJ; Francis RJ; Galloway DB; Humphreys JE
Eur J Clin Pharmacol; 1986; 31(1):113-5. PubMed ID: 2877883
[TBL] [Abstract][Full Text] [Related]
10. Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker.
Swerdlow CD; Peterson J; Turlapaty P
Am Heart J; 1986 Jan; 111(1):49-53. PubMed ID: 2868646
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias.
Steinberg JS; Katz RJ; Somberg JC; Keefe D; Laddu AR; Burge J
Am J Cardiol; 1986 Nov; 58(10):1005-8. PubMed ID: 2877563
[TBL] [Abstract][Full Text] [Related]
12. Effects of flestolol, an ultra-short acting beta-adrenoceptor antagonist, on hemodynamic changes produced by treadmill exercise or isoprenaline stimulation in conscious dogs.
Grohs JG; Fischer G; Raberger G
J Cardiovasc Pharmacol; 1990 Feb; 15(2):175-81. PubMed ID: 1689410
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and urinary excretion of esmolol in humans.
Achari R; Drissel D; Matier WL; Hulse JD
J Clin Pharmacol; 1986 Jan; 26(1):44-7. PubMed ID: 2869058
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Thebault JJ; Trocherie S; Morselli PL
Arzneimittelforschung; 1980; 30(11):1912-6. PubMed ID: 6109538
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.
Wiedemann I; Peil H; Justus H; Adamus S; Brantl V; Lohmann H
Arzneimittelforschung; 1985; 35(6):964-9. PubMed ID: 2862877
[TBL] [Abstract][Full Text] [Related]
17. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.
Selen A; Kinkel AW; Darke AC; Greene DS; Welling PG
Eur J Clin Pharmacol; 1986; 30(6):699-704. PubMed ID: 2876899
[TBL] [Abstract][Full Text] [Related]
18. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.
Morita S; Iinuma M; Kido M; Sakuragi S; Kohri H; Nishino H
Arzneimittelforschung; 1977; 27(12):2380-3. PubMed ID: 23800
[TBL] [Abstract][Full Text] [Related]
19. Absolute bioavailability study in the dog with Visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity.
McAinsh J; Smith RP; Ferguson RA
Eur J Drug Metab Pharmacokinet; 1984; 9(2):129-39. PubMed ID: 6146530
[TBL] [Abstract][Full Text] [Related]
20. Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist.
Fischer G; Grohs JG; Raberger G
Cardiovasc Res; 1990 Feb; 24(2):115-20. PubMed ID: 1970278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
